home
portfolio
team
careers
contact
investor portal

home
portfolio
team
careers
contact
investor portal

Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates

Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates

Post navigation

Previous PostPrevious Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

Next PostNext IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Search for:

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

© Nextech Invest Ltd. | privacy policy | legal notices